163 related articles for article (PubMed ID: 11800031)
1. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Chang DZ; Olencki T; Budd GT; Peereboom D; Ganapathi R; Osterwalder B; Bukowski R
Cancer Chemother Pharmacol; 2001 Dec; 48(6):493-8. PubMed ID: 11800031
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Villalona-Calero MA; Blum JL; Jones SE; Diab S; Elledge R; Khoury P; Von Hoff D; Kraynak M; Moczygemba J; Kromelis P; Griffin T; Rowinsky EK
Ann Oncol; 2001 May; 12(5):605-14. PubMed ID: 11432617
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
Segota E; Mekhail T; Olencki T; Hutson TE; Dreicer R; Wacker B; Osterwalder B; Elson P; Zhou M; Bukowski RM
Urol Oncol; 2007; 25(1):46-52. PubMed ID: 17208138
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Padrik P; Leppik K; Arak A
Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Ramanathan RK; Ramalingam S; Egorin MJ; Belani CP; Potter DM; Fakih M; Jung LL; Strychor S; Jacobs SA; Friedland DM; Shin DM; Chatta GS; Tutchko S; Zamboni WC
Cancer Chemother Pharmacol; 2005 Apr; 55(4):354-360. PubMed ID: 15723261
[TBL] [Abstract][Full Text] [Related]
6. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.
Cassidy J; Dirix L; Bissett D; Reigner B; Griffin T; Allman D; Osterwalder B; Van Oosterom AT
Clin Cancer Res; 1998 Nov; 4(11):2755-61. PubMed ID: 9829739
[TBL] [Abstract][Full Text] [Related]
7. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
Saeki T; Takashima S; Terashima M; Satoh A; Toi M; Osaki A; Toge T; Ohno S; Nomura N; Fukuyama Y; Koizumi W; Taguchi T
Int J Clin Oncol; 2005 Feb; 10(1):51-7. PubMed ID: 15729602
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.
Pivot X; Chamorey E; Guardiola E; Magné N; Thyss A; Otto J; Giroux B; Mouri Z; Schneider M; Milano G
Ann Oncol; 2003 Oct; 14(10):1578-86. PubMed ID: 14504061
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
Díaz-Rubio E; Evans TR; Tabemero J; Cassidy J; Sastre J; Eatock M; Bisset D; Regueiro P; Baselga J
Ann Oncol; 2002 Apr; 13(4):558-65. PubMed ID: 12056706
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Undevia SD; Kindler HL; Janisch L; Olson SC; Schilsky RL; Vogelzang NJ; Kimmel KA; Macek TA; Ratain MJ
Ann Oncol; 2004 Nov; 15(11):1705-11. PubMed ID: 15520075
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC
Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; Semiond D; deJonge MJ; Eskens FA; ter Steeg J; Selleslach J; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
J Clin Oncol; 2005 Feb; 23(4):889-98. PubMed ID: 15681535
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
[TBL] [Abstract][Full Text] [Related]
15. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Villalona-Calero MA; Weiss GR; Burris HA; Kraynak M; Rodrigues G; Drengler RL; Eckhardt SG; Reigner B; Moczygemba J; Burger HU; Griffin T; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Jun; 17(6):1915-25. PubMed ID: 10561233
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Mackean M; Planting A; Twelves C; Schellens J; Allman D; Osterwalder B; Reigner B; Griffin T; Kaye S; Verweij J
J Clin Oncol; 1998 Sep; 16(9):2977-85. PubMed ID: 9738566
[TBL] [Abstract][Full Text] [Related]
18. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Amato RJ; Khan M
Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
[TBL] [Abstract][Full Text] [Related]
20. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]